Absci Corporation Stock News

VANCOUVER, Wash., March 16, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a drug and target discovery company harnessing deep learning, AI and synthetic biology to expand the therapeuti

VANCOUVER, Wash., March 16, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a drug and target discovery company harnessing deep learning, AI and synthetic biology to expand the therapeutic

Absci (ABSI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Absci (ABSI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

VANCOUVER, Wash., March 01, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI ), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced that Sean McClain, CEO & Founder, will be participating on the Synthetic Biology Enabling Drug Discovery Panel at the Cowen 42 nd Annual Health Care Conference. The panel is scheduled to take place on March 8 th , 2022 at 12:30-1:30 p.m. Pacific Time / 3:30-4:30 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the company''s investor relations website at: investors.absci.com . About Absci Absci is … Full story available on Benzinga.com

VANCOUVER, Wash., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic

In the last trading session, 1.42 million shares of the Absci Corporation (NASDAQ:ABSI) were traded. Most recently the company’s share price was $8.83, and it changed around $0.05 or 0.57% from the last close, which brings the market valuation of the company to $799.73M. ABSI currently trades at a discount to its 52-week high of … Future Outlook And Stock Price Performance For Absci Corporation (NASDAQ: ABSI) Read More »

VANCOUVER, Wash., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeuti

VANCOUVER, Wash., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating virtually in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

The following slide deck was published by Absci Corporation in conjunction with this event.

Regulatory and other pipeline updates from Biogen (BIIB) and AMGN are among a few key highlights from the biotech sector during the past week.

Absci (ABSI) signs a deal with Merck for using its AI-powered drug creation platform to produce enzymes for Merck's biomanufacturing applications with an option for the development of three novel drug

Absci (ABSI) signs a deal with Merck for using its AI-powered drug creation platform to produce enzymes for Merck's biomanufacturing applications with an option for the development of three novel drug

Absci Corp (ABSI) shares closed today 17.1% higher than it did at the end of yesterday. The stock is currently down 12.3% year-to-date, down 66.7% over the past 12 months, and down 66.7% over the past five years. Today, the Dow Jones Industrial Average fell 0.0%, and the S&P 500 fell 0.4%. Trading Activity Shares traded as high as $9.26 and as low as $6.12 this week.Shares closed 77.2% below its 52-week high and 17.5% above its 52-week low.Trading volume this week was 90.5% lower than the 10-day average and 75.6% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 4626.4% The company's stock price performance over the past 12 months lags the peer average by 662.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Absci (ABSI) stock is flying higher on Friday after announcing a major research collaboration agreement with Merck (MRK).